Senior Director of Medical Affairs Presents at Rural Medicine Australia 2018 in Darwin, Australia
Darwin, Australia – Oct 27, 2018 – Rural Medicine Australia 2018 (RMA18) is the annual conference hosted by the Australian College of Remote and Rural Medicine (ACRRM) and the Rural Doctors Association of Australia (RDAA). This year’s conference was held in Darwin, Australia and was attended by over 750 healthcare professionals including GPs and academics. RMA18 is considered a national event for rural doctors, both in Australia and internationally.
At RMA18, DermaSensor’s Senior Director of Medical Affairs, Dr. Michael Bonning, presented on “Optical Spectroscopy as a Potential Adjunctive Tool for Skin Cancer Risk Assessment.” Dr. Bonning’s presentation focused on using Elastic Scattering Spectroscopy (ESS) as a technology that can be applied in a device and be used to assist all clinicians (GPs, nurses, etc.) in their assessment of skin lesions.
DermaSensor is a handheld device, developed by DermaSensor Inc., that uses artificial intelligence and ESS to evaluate skin lesions. The device uses ESS by emitting lights particles, which hit the surface of the lesion and are reflected back to the device. Different tissue types and histopathological status exhibit specific optical signatures, and ESS has been demonstrated clinically to assess malignancy in multiple tissue types.
According to Dr. Bonning, “The ESS system and the machine-learning classifier reported here demonstrate that this technology offers the potential to provide reproducible, actionable information for practitioners.”
About Dr. Michael Bonning:
Dr. Michael Bonning, Senior Director of Medical Affairs, is an Australian-qualified medical practitioner (General Practice/Public Health/Armed Forces) with extensive experience in health policy advisory to Government, non-profit and corporations. During his 12 years with the Royal Australian Navy he was deployed on multiple international operations, whilst concurrently building a significant policy advisory consulting firm and serving on some of Australia’s most influential health-focused boards. He has spent four years as a director of the largest primary health care residency program in Australia. Michael is an adjunct fellow at Macquarie University and takes a public health approach to skin cancer management and the value of early identification and management. Michael has used his experience to advise political campaigns, advocacy organizations and help steer not-for-profit organizations. He likes social media and has provided advice on the social media aspects of advocacy and political campaigns. He believes that better leadership is vital for a healthy Australia and is working on public health strategies that deal with equity and financial autonomy. He is a sought-after speaker on physician health and healthcare leadership as a result of his unique experiences across government, leadership and medicine.
About the Company:
DermaSensor Inc. is a Miami-based connected device company that enables healthcare professionals to efficiently check for skin cancer by leveraging cutting-edge technologies. The DermaSensor device is an affordable handheld tool that uses artificial intelligence and spectroscopy to evaluate skin lesions for potential cancer in a matter of seconds. By enabling quick and effective skin cancer checks, DermaSensor hopes to ultimately improve patient outcomes. To learn more, visit www.dermasensor.com.